Search results
Showing results for
PGN-EDODM1 was generally well-tolerated, with all adverse events being mild or moderate, and no serious adverse events reported. The mean splicing correction observed with PGN-EDODM1 (n=6) was 7.3%, compared to 6.8% for the placebo (n=2). Excluding one outlier patient, the treatment group showed a mean splicing correction of 22.9% (n=5). Promising trends were seen in vHOT in the PGN-EDODM1 treated group. The company is on track to report clinical data from the 10 mg/kg multiple dose cohort in the second half of 2026, with sufficient cash expected to fund operations into the second half of 2027.
Accessibility Statement
The University of Oxford is committed to providing an accessible web presence that gives members of the public and members of the University community full access to University information, courses and activities offered publicly through the web. Our Equality Policy outlines our commitment to a culture which ‘maintains a working, learning and social environment in which the rights and dignity of all its staff and students are respected’.
"We loved being in the BioEscalator, and part of the community, and the support and flexibility from the BioEscalator team was invaluable."
Hollie Coe, Base Genomics (now Exact Sciences Innovation)
"The high-quality facilities, resources and support to grow a company were invaluable."
Tim Funnell, MiroBio (now Gilead)
